Results 71 to 80 of about 31,062 (287)

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Effect on Mortality of Higher Versus Lower β-Blocker (Metoprolol Succinate or Carvedilol) Dose in Patients With Heart Failure [PDF]

, 2018
This study aimed to compare the effect of β-blocker dose and heart rate (HR) on mortality in patients with heart failure with reduced ejection fraction (HFrEF).
Ajam, Samer, Ajam, Tarek, Devaraj, Srikant, Fudim, Marat, Kamalesh, Masoor   +4 more
core   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model

Clinical Epidemiology, 2020
Moa P Lee,1,2 Robert J Glynn,1 Sebastian Schneeweiss,1 Kueiyu Joshua Lin,1,3 Elisabetta Patorno,1 Julie Barberio,1 Raisa Levin,1 Thomas Evers,4 Shirley V Wang,1 Rishi J Desai1 1Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women ...
Lee MP, Glynn RJ, Schneeweiss S, Lin KJ, Patorno E, Barberio J, Levin R, Evers T, Wang SV, Desai RJ   +9 more
doaj  

Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients

BMC Nephrology, 2020
Background Peritoneal ultrafiltration (pUF) in refractory heart failure (HF) reduces the incidence of decompensation episodes, which is of particular significance as each episode incrementally adds to mortality.
Leonie Grossekettler, Bastian Schmack, Carsten Brockmann, Reinhard Wanninger, Michael M. Kreusser, Lutz Frankenstein, Lars P. Kihm, Martin Zeier, Hugo A. Katus, Vedat Schwenger, Andrew Remppis   +10 more
doaj   +1 more source

P217 SHORT–TERM EFFECTS OF DAPAGLIFLOZIN ON CARDIAC BIOMARKERS, FLUID RETENTION, RENAL AND PULMONARY FUNCTION IN HFREF PATIENTS: NOT AS GOOD AS EXPECTED [PDF]

, 2023
Massimo Mapelli, T Capovilla, Andrea Marongiu, G Maranzano, Elisabetta Salvioni, Irene Mattavelli, C Paganin, Carlo Vignati, Paola Gugliandolo, Valentina Mantegazza, Anna Garlaschè, Gianfranco Sinagra, Piergiuseppe Agostoni   +12 more
openalex   +1 more source

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

ESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller, Tobias Harm, Manuel Sigle, Parwez Aidery, Klaus‐Peter Kreisselmeier, Livia Baas, Andreas Goldschmied, Meinrad Paul Gawaz, Karin Anne Lydia Müller   +8 more
wiley   +1 more source

Novel pathways of heart failure with preserved ejection fraction [PDF]

, 2016
INTRODUCTION: Diastolic heart failure (HF) i.e., HF with preserved ejection fraction (HFpEF) accounts for ~50% of all clinical HF presentations; but unlike systolic HF i.e., HF with reduced ejection fraction (HFrEF), there are no evidenced based ...
Li, Shanpeng
core   +2 more sources

Knowledge and Practices regarding Guideline-directed Medical Therapy for Heart Failure with Reduced Ejection Fraction (HFrEF) among Physicians in Beijing, China: a Cross- sectional Study [PDF]

, 2023
Ying Xie, Yintang Wang, Yu Geng, Lanting Zhao, Fei Wang, Fei She, Ping Zhang   +6 more
openalex   +1 more source